Adherex Technologies (NASDAQ:FENC) Issues Quarterly Earnings Results

Adherex Technologies (NASDAQ:FENC) posted its earnings results on Tuesday. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Zacks reports. Adherex Technologies had a negative return on equity of 43.87% and a negative net margin of 17.12%.

Here are the key takeaways from Adherex Technologies’ conference call:

• PEDMARK net product sales rose 78% year over year to $17.1 million in Q2 2026, marking the company’s seventh consecutive quarter of growth. Non-GAAP adjusted EBITDA improved to $2.8 million from a $1.2 million loss a year ago.
• Commercial momentum accelerated, with Q2 demand up double digits sequentially, record patient enrollments and infusions, and a 280% increase in sales calls. July produced all-time highs for completed infusions, new enrollments, active patients, and new customers, while the expanded sales force now reaches roughly 5,000 targets.
• Medical and clinical efforts are expanding, including three actively accruing investigator-sponsored studies and an upcoming oral presentation of Japan’s STS-J01 trial data at SIOP 2026. Management said maturing data could support future label expansions and stronger NCCN recommendations, while discussions with potential Japanese and Asia-Pacific partners continue.
• Operating expenses excluding stock-based compensation increased to approximately $13.6 million, driven largely by higher commercial headcount and marketing investments. Management expects cash to decline in Q3 due to customer collection cycles, although it anticipates positive cash generation in Q4 and year-end cash.

Adherex Technologies Trading Up 7.5%

FENC stock traded up $0.82 during trading on Tuesday, reaching $11.76. The stock had a trading volume of 203,428 shares, compared to its average volume of 203,190. The firm has a market cap of $412.17 million, a PE ratio of -40.57 and a beta of 1.09. The stock’s 50 day moving average is $10.02 and its two-hundred day moving average is $8.51. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $13.25.

Institutional Investors Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC purchased a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on FENC. Wedbush reaffirmed an “outperform” rating and set a $13.00 price objective on shares of Adherex Technologies in a research report on Thursday, April 16th. HC Wainwright boosted their target price on Adherex Technologies from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Zacks Research upgraded shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Wall Street Zen raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.40.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.